Abstract
A bispecific ligand-directed toxin (BLT), called EGFATFKDEL, consisting of human epidermal growth factor, a fragment of urokinase, and truncated pseudomonas exotoxin (PE38) was assembled in order to target human glioblastoma. Immunogenicity was reduced by mutating seven immunodominant B-cell epitopes on the PE38 molecule to create a new agent, EGFATFKDEL 7mut. In vitro, the drug selectively killed several human glioblastoma cell lines. EGFATFKDEL is our first BLT designed to simultaneously target EGFR on solid tumors and uPAR on the tumor neovasculature. In vitro assays revealed that the agent is effective against glioblastoma cell lines as well as human umbilical vein endothelial cells (HUVEC). Additionally, the bispecific drug displayed enhanced binding to overexpressed epidermal growth factor receptor and urokinase receptor when compared to similar monospecific drugs, EGFKDEL and ATFKDEL. In vivo, an aggressive human glioblastoma cell line was genetically marked with a firefly luciferase reporter gene and administered to the flanks of nude mice. Treatment with intratumoral injections of EGFATFKDEL 7mut eradicated small tumors in over half of the treated mice, which survived with tumor free status at least 100 days post tumor inoculation. ATFKDEL, which primarily targets the tumor neovasculature, prevented tumor growth but did not result in tumor-free mice in most cases. Specificity was shown by treating with an irrelevant BLT control which did not protect mice. Finally, immunization experiments in immunocompetent mice revealed significantly reduced anti-toxin production in EGFATFKDEL 7mut treated groups. Thus, EGFATFKDEL 7mut is an effective drug for glioblastoma therapy in this murine model and warrants further study.
Similar content being viewed by others
References
Lowe S, Schmidt U, Unterberg A, Halatsch ME (2009) The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 9:703–715
Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK (2006) Convection-enhanced delivery of interleukin-14 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 5:239–250
Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nat Med 3:1362–1368
Hall WA, Vallera DA (2006) Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg Focus 20:E23
Fuchs H, Bachran C (2009) Targeted tumor therapies at a glance. Curr Drug Targets 10:89–93
Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA (2009) Design and modification of EGF4KDEL 7mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 101:1114–1123
Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP (2009) Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 33:1233–1242
Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortarti A, Vallera DA (2007) A bispecific recombinant cytotoxin (DTEGF13) targeting human IL-13 and EGF receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res 13:6486–6493
Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 15:3058–3067
Pastan I, Chaudhary V, FitzGerald DJ (1992) Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 61:331–354
Kreitman RJ, Pastan I (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 58:968–975
Kreitman RJ, Pastan I (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307:29–37
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137
Pytel P, Lukas RV (2009) Update on diagnostic practice: tumors of the nervous system. Arch Pathol Lab Med 133:1062–1077
Wang MY, Lu KV, Zhu S et al (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66:7864–7869
Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D (2005) Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 4:1369–1372
Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142
Mori T, Abe T, Wakabayashi Y et al (2000) Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-α or basic fibroblast growth factor. J Neurooncol 46:115–123
Grondahl-Hansen J, Peters HA, van Putten WL et al (1995) Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1:1079–1087
Verspaget HW, Sier CF, Ganesh S, Griffoen G, Lamers CB (1995) Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 31:1105–1109
Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR (2004) Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 103:955–962
Choong PF, Nadesapillai AP (2003) Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 415(Supple):S46–S58
Rustamzadeh E, Hall WA, Todhunter DA et al (2006) Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer 120:411–419
Hassan R, Bullock S, Premkumar A et al (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144–5149
Onda M, Nagata S, FitzGerald DJ et al (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 177:8822–8834
Vogelbaum MA, Sampson JH, Kunwar S et al (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61:1031–1037
Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H (2005) A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 11:3879–3888
Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA (2002) Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Nat Cancer Inst 94:597–605
Vallera DA, Todhunter D, Kuroki DW, Shu Y, Sicheneder A, Panoskaltsis-Mortari A, Vallera VD, Chen H (2005) Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res 29:331–341
Vallera DA, Shu Y, Chen H et al (2008) Genetically designing a more potent anti-pancreatic cancer agent by simultaneously cotargeting human IL-13 and EGF receptors in a mouse xenograft model. Gut 57:634–641
Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverley PC, Neville DM Jr, Youle RJ (1983) Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222:512–515
Vallera DA, Taylor PA, Sprent J, Blazar BR (1994) The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatability complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249–256
Nagata S, Pastan I (2009) Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev 61:977–985
Onda M, Beers R, Xiang L, Nagata S, Wang Q, Pastan I (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. PNAS 105:11311–11316
Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA (2009) A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res 15:6137–6147
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257
Kreitman RJ, Stetler-Stevenson M, Margulies I et al (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27:2983–2990
Oh S, Ohlfest JR, Todhunter DA et al (2009) Intracranial elimination of glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol 95:331–342
Ho M, Nagata S, Pastan I (2006) Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci USA 103:9637–9642
Acknowledgments
This work was supported in part by the US Public Health Service Grants RO1-CA36725 and RO1-CA082154 awarded by the NCI and the NIAID, DHHS and the Martha L. Kramer Fund. We thank Travis M. Spangler and Zintis Inde for assistance. This manuscript partially fulfilled requirements for the Master of Science degree for A. Tsai, CLS program, University of Minnesota.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsai, A.K., Oh, S., Chen, H. et al. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol 103, 255–266 (2011). https://doi.org/10.1007/s11060-010-0392-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0392-5